This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Lormetazepam: Difference between revisions
Jump to navigation
Jump to search
>Follabras112 Created page with "Lormetazepam (sold commercially as Noctamid, Sedalam, Ergocalm and others) is a short to intermediate acting 3-hydroxy benzodiazepine derivative and temazepam analogue." |
>Follabras112 No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Lormetazepam (sold commercially as Noctamid, Sedalam, Ergocalm and others) is a short to intermediate acting 3-hydroxy benzodiazepine derivative and temazepam analogue. | {{DepressantOD|benzodiazepines}} | ||
{{SummarySheet}} | |||
'''Lormetazepam''' (trade name '''Nocatmid''' or '''Loretam''') is a [[psychoactive class::depressant]] substance of the [[chemical class::benzodiazepine]] class. Lorazepam is used for the short-term treatment of, [[insomnia]], [[seizure|acute seizures]], and the sedation of hospitalized patients.<ref>{{Citation | title=benzo.org.uk : Benzodiazepines and their effects, Professor Ian Hindmarch, January, 1997 | url=https://www.benzo.org.uk/hindmarch.htm}}</ref><ref>{{cite journal | vauthors=((Cox, C. E.)), ((Reed, S. D.)), ((Govert, J. A.)), ((Rodgers, J. E.)), ((Campbell-Bright, S.)), ((Kress, J. P.)), ((Carson, S. S.)) | journal=Critical care medicine | title=An Economic Evaluation of Propofol and Lorazepam for Critically Ill Patients Undergoing Mechanical Ventilation | volume=36 | issue=3 | pages=706–714 | date= March 2008 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763279/ | issn=0090-3493 | doi=10.1097/CCM.0B013E3181544248}}</ref><ref>{{cite journal | vauthors=((Walker, M.)) | journal=BMJ : British Medical Journal | title=Status epilepticus: an evidence based guide | volume=331 | issue=7518 | pages=673–677 | date=24 September 2005 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1226249/ | issn=0959-8138}}</ref><ref>{{cite journal | vauthors=((Battaglia, J.)) | journal=Drugs | title=Pharmacological Management of Acute Agitation | volume=65 | issue=9 | pages=1207–1222 | date=1 June 2005 | url=https://doi.org/10.2165/00003495-200565090-00003 | issn=1179-1950 | doi=10.2165/00003495-200565090-00003}}</ref> | |||
Lormetazepam (sold commercially as Noctamid, Sedalam, Ergocalm and others) is a short acting depressant benzodiazepine to intermediate acting 3-hydroxy benzodiazepine derivative and temazepam analogue. | |||
It's used for the short-term treatment of moderate to severe insomnia, and to induce sleep in pre- and postoperative periods. | |||
<references /> | |||
Latest revision as of 02:25, 17 May 2025
Fatal overdose may occur when benzodiazepines are combined with other depressants such as opiates, barbiturates, gabapentinoids, thienodiazepines, alcohol or other GABAergic substances.[1]
It is strongly discouraged to combine these substances, particularly in common to heavy doses.
| Summary sheet: Lormetazepam |
Lormetazepam (trade name Nocatmid or Loretam) is a depressant substance of the benzodiazepine class. Lorazepam is used for the short-term treatment of, insomnia, acute seizures, and the sedation of hospitalized patients.[2][3][4][5] Lormetazepam (sold commercially as Noctamid, Sedalam, Ergocalm and others) is a short acting depressant benzodiazepine to intermediate acting 3-hydroxy benzodiazepine derivative and temazepam analogue.
It's used for the short-term treatment of moderate to severe insomnia, and to induce sleep in pre- and postoperative periods.
- ↑ Risks of Combining Depressants - TripSit
- ↑ benzo.org.uk : Benzodiazepines and their effects, Professor Ian Hindmarch, January, 1997
- ↑ Cox, C. E., Reed, S. D., Govert, J. A., Rodgers, J. E., Campbell-Bright, S., Kress, J. P., Carson, S. S. (March 2008). "An Economic Evaluation of Propofol and Lorazepam for Critically Ill Patients Undergoing Mechanical Ventilation". Critical care medicine. 36 (3): 706–714. doi:10.1097/CCM.0B013E3181544248. ISSN 0090-3493.
- ↑ Walker, M. (24 September 2005). "Status epilepticus: an evidence based guide". BMJ : British Medical Journal. 331 (7518): 673–677. ISSN 0959-8138.
- ↑ Battaglia, J. (1 June 2005). "Pharmacological Management of Acute Agitation". Drugs. 65 (9): 1207–1222. doi:10.2165/00003495-200565090-00003. ISSN 1179-1950.